Skip to content
Parakho

Ind-Swift Laboratories Ltd

NSE INDSWFTLABBSE 532305

Q1 FY27, unaudited

Revenue
₹186.08 Cr
Profit after tax
₹24.44 Cr

As filed with the exchange, standalone basis.

Statement of profit and loss

Figures in ₹ crore, reproduced from the results data files the company filed with NSE under Regulation 33 of the SEBI (LODR) Regulations. Nothing is restated, adjusted or estimated.

Statement of profit and loss, standalone basis
₹ croreQ1 FY27vs a year agoFY26
Revenue from operations186.08+25.74%635.89
Other income7.63−47.69%46.96
Total income193.71+19.15%682.84
Employee benefit expense38.95+21.71%136.33
Finance costs0.71−38.76%1.40
Depreciation & amortisation7.58+13.57%30.57
Total expenses161.05+5.43%621.62
Profit before tax32.43+230.04%50.22
Tax expense7.98+368.03%7.66
Profit after tax24.44+201.05%42.56
Total comprehensive income24.44+201.05%41.68
Earnings per share
Earnings per share, basic₹2.81₹5.09
Earnings per share, diluted₹2.81₹4.97

Q1 FY27 — unaudited, from the company’s filing with NSE. Source

Q1 FY26, the year-ago base — unaudited, from the company’s filing with NSE. Source

FY26 — from the company’s filing with NSE. Source

Q1 FY27 results for every company Parakho holds

Earnings call

Q1 FY27

Ind-Swift Laboratories reported Q1 FY27 operating income of ₹186.08 crore, up 21.16% year-on-year, with operating EBITDA more than doubling to ₹33.32 crore and EBITDA margin expanding to 17.91%. Management said the export segment, particularly own-brand sales, grew to 57.20% of quarterly sales from 48% a year earlier, while newly commercialised CDMO partnerships with Viatris, Manx and Arrotex contributed modest revenue in the quarter. Management discussed capacity expansion, capital allocation of approximately ₹250 crore of cash over roughly two to two-and-a-half years, and provided updates on dossier filings, product registrations, and the Samba facility upgrade to EU-GMP and PIC/S standards.

Generated by AI from the filed transcript; every statement on the full page carries its verbatim quote.

Read the full summary

Filings

12 shown · 64 published by the exchange

BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.

Industry

Healthcare › Pharmaceuticals

Classification as published by BSE.

Companies also in Pharmaceuticals, in alphabetical order

All 196 companies in Pharmaceuticals

Page generated from filings held to 12 Oct 2026.